Literature DB >> 33298540

Escape of HIV-1 envelope glycoprotein from the restriction of infection by IFITM3.

Aurélie Drouin1, Julie Migraine1, Marie-Alice Durand1, Alain Moreau1, Julien Burlaud-Gaillard1,2, Maxime Beretta1, Philippe Roingeard1,2, Mélanie Bouvin-Pley1, Martine Braibant3.   

Abstract

Interferon-induced transmembrane protein 3 (IFITM3) is a cellular factor that reduces HIV-1 infectivity by an incompletely understood mechanism. We show here that viruses differing only in the envelope glycoprotein (Env) expressed on their surface have different sensitivities to IFITM3. Measurements of the sensitivity of viruses to neutralizing antibodies showed that IFITM3 increased the sensitivity of IFITM3-sensitive viruses to PG16, which targets the V1V2 loop, suggesting that IFITM3 promotes exposure of the PG16 epitope of IFITM3-sensitive viruses. Exchanges of V1V2 loops between the Env proteins of sensitive and resistant viruses revealed that V1V2 and V3 act together to modulate viral sensitivity to IFITM3. Co-immunoprecipitation experiments showed that IFITM3 interacted with both the precursor (gp160) and cleaved (gp120) forms of Env from IFITM3-sensitive viruses, but only with the precursor (gp160) form of Env from IFITM3-resistant viruses. This finding suggests that the interaction between the Env of resistant viruses and IFITM3 was inhibited once Env had been processed in the Golgi apparatus. This hypothesis was supported by immunofluorescence experiments, which showed a strong colocalization of IFITM3 with the Env of sensitive viruses, but only weak colocalization with the Env of resistant viruses on the plasma membrane of virus-producing cells. Together, these results indicate that IFITM3 interacts with Env, inducing conformational changes that may decrease viral infectivity. This antiviral action is, nevertheless, modulated by the nature of the Env, in particular its V1V2 and V3 loops, which after maturation may be able to escape this interaction.IMPORTANCE Interferon-induced transmembrane protein 3 (IFITM3) is a cellular factor that reduces HIV-1 infectivity by an incompletely understood mechanism. This study aimed to elucidate the role of the HIV-1 envelope glycoprotein (Env) in determining viral susceptibility to IFITM3. We found that viruses differing only in Env expressed on their surface had different sensitivities to IFITM3. By comparing the Env proteins of viruses that were highly sensitive or resistant to IFITM3, we obtained new insight in the mechanisms by which HIV-1 escapes this protein. We showed that IFITM3 interacts with the Env protein of sensitive viruses in virion-producing cells, inducing conformational changes that may decrease viral infectivity. However, this antiviral action is modulated by the nature of Env, particularly the V1V2 and V3 loops, which may be able to escape this interaction after processing in the Golgi.
Copyright © 2020 American Society for Microbiology.

Entities:  

Year:  2020        PMID: 33298540      PMCID: PMC8092819          DOI: 10.1128/JVI.01994-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication.

Authors:  Sinu P John; Christopher R Chin; Jill M Perreira; Eric M Feeley; Aaron M Aker; George Savidis; Sarah E Smith; Andrew E H Elia; Aaron R Everitt; Mehul Vora; Thomas Pertel; Stephen J Elledge; Paul Kellam; Abraham L Brass
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

2.  Interferon induction of IFITM proteins promotes infection by human coronavirus OC43.

Authors:  Xuesen Zhao; Fang Guo; Fei Liu; Andrea Cuconati; Jinhong Chang; Timothy M Block; Ju-Tao Guo
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-21       Impact factor: 11.205

3.  Functional Mapping of Regions Involved in the Negative Imprinting of Virion Particle Infectivity and in Target Cell Protection by Interferon-Induced Transmembrane Protein 3 against HIV-1.

Authors:  Mathilde Delpeuch; Li Zhong; Romain Appourchaux; Julien Burlaud-Gaillard; Kevin Tartour; George Savidis; Abraham Brass; Lucie Etienne; Philippe Roingeard; Andrea Cimarelli
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

4.  Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses.

Authors:  Xuesen Zhao; Mohit Sehgal; Zhifei Hou; Junjun Cheng; Sainan Shu; Shuo Wu; Fang Guo; Sylvain J Le Marchand; Hanxin Lin; Jinhong Chang; Ju-Tao Guo
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

5.  Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus.

Authors:  I-Chueh Huang; Charles C Bailey; Jessica L Weyer; Sheli R Radoshitzky; Michelle M Becker; Jessica J Chiang; Abraham L Brass; Asim A Ahmed; Xiaoli Chi; Lian Dong; Lindsay E Longobardi; Dutch Boltz; Jens H Kuhn; Stephen J Elledge; Sina Bavari; Mark R Denison; Hyeryun Choe; Michael Farzan
Journal:  PLoS Pathog       Date:  2011-01-06       Impact factor: 6.823

6.  Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs.

Authors:  Kevin Tartour; Xuan-Nhi Nguyen; Romain Appourchaux; Sonia Assil; Véronique Barateau; Louis-Marie Bloyet; Julien Burlaud Gaillard; Marie-Pierre Confort; Beatriz Escudero-Perez; Henri Gruffat; Saw See Hong; Marie Moroso; Olivier Reynard; Stéphanie Reynard; Elodie Decembre; Najate Ftaich; Axel Rossi; Nannan Wu; Frédérick Arnaud; Sylvain Baize; Marlène Dreux; Denis Gerlier; Glaucia Paranhos-Baccala; Viktor Volchkov; Philippe Roingeard; Andrea Cimarelli
Journal:  PLoS Pathog       Date:  2017-09-28       Impact factor: 6.823

7.  Opposing activities of IFITM proteins in SARS-CoV-2 infection.

Authors:  Guoli Shi; Adam D Kenney; Elena Kudryashova; Ashley Zani; Lizhi Zhang; Kin Kui Lai; Luanne Hall-Stoodley; Richard T Robinson; Dmitri S Kudryashov; Alex A Compton; Jacob S Yount
Journal:  EMBO J       Date:  2020-12-21       Impact factor: 11.598

8.  The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus.

Authors:  Abraham L Brass; I-Chueh Huang; Yair Benita; Sinu P John; Manoj N Krishnan; Eric M Feeley; Bethany J Ryan; Jessica L Weyer; Louise van der Weyden; Erol Fikrig; David J Adams; Ramnik J Xavier; Michael Farzan; Stephen J Elledge
Journal:  Cell       Date:  2009-12-24       Impact factor: 41.582

9.  IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein.

Authors:  Jingyou Yu; Minghua Li; Jordan Wilkins; Shilei Ding; Talia H Swartz; Anthony M Esposito; Yi-Min Zheng; Eric O Freed; Chen Liang; Benjamin K Chen; Shan-Lu Liu
Journal:  Cell Rep       Date:  2015-09-17       Impact factor: 9.423

10.  IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion.

Authors:  Tanay M Desai; Mariana Marin; Christopher R Chin; George Savidis; Abraham L Brass; Gregory B Melikyan
Journal:  PLoS Pathog       Date:  2014-04-03       Impact factor: 6.823

View more
  4 in total

1.  Transmembrane domain of IFITM3 is responsible for its interaction with influenza virus HA2 subunit.

Authors:  Wang Xu; Yuhang Wang; Letian Li; Xiaoyun Qu; Quan Liu; Tiyuan Li; Shipin Wu; Ming Liao; Ningyi Jin; Shouwen Du; Chang Li
Journal:  Virol Sin       Date:  2022-07-06       Impact factor: 6.947

Review 2.  HIV-1 entry: Duels between Env and host antiviral transmembrane proteins on the surface of virus particles.

Authors:  Tomoyuki Murakami; Akira Ono
Journal:  Curr Opin Virol       Date:  2021-08-12       Impact factor: 7.121

3.  HIV-1 Envelope Glycoproteins Proteolytic Cleavage Protects Infected Cells from ADCC Mediated by Plasma from Infected Individuals.

Authors:  Jérémie Prévost; Halima Medjahed; Dani Vézina; Hung-Ching Chen; Beatrice H Hahn; Amos B Smith; Andrés Finzi
Journal:  Viruses       Date:  2021-11-06       Impact factor: 5.818

Review 4.  Membrane Interference Against HIV-1 by Intrinsic Antiviral Factors: The Case of IFITMs.

Authors:  Federico Marziali; Andrea Cimarelli
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.